Safety efficacy of open-label dupilumab in adult patients with moderate-to-severe atopic dermatitis: an analysis up to 3 years (LIBERTY AD OLE)

被引：0
|
作者：
Thaci, D. [1 ]
Deleuran, M. [2 ]
Bissonnette, R. [3 ]
Bouaziz, J. D. [4 ]
Sun, X. [5 ]
Patel, N. [6 ]
Shumel, B. [5 ]
机构：
[1] Univ Lubeck, Lubeck, Germany
[2] Aarhus Univ Hosp, Aarhus, Denmark
[3] Innovaderm Res, Montreal, PQ, Canada
[4] Hop St Louis, Paris, France
[5] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[6] Sanofi, Bridgewater, NJ USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2020年 / 183卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P01
引用
收藏
页码：E94 / E94
页数：1
相关论文
共 50 条
  • [31] Dupilumab provides long-term efficacy for up to 4 years in an open-label extension study of adults with moderate-to-severe atopic dermatitis
    Thyssen, J. P.
    Blauvelt, A.
    Lockshin, B.
    Galus, R.
    Lynde, C.
    Xiao, J.
    Levit, N. A.
    Marco, A. R.
    Shabbir, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E162 - E162
  • [32] DUPILUMAB PROVIDES LONG-TERM EFFICACY FOR UP TO 4 YEARS IN AN OPEN-LABEL EXTENSION STUDY OF ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Deleuran, Mette
    Blauvelt, Andrew
    Thyssen, Jacob P.
    Lockshin, Benjamin
    Galus, Ryszard
    Lynde, Charles
    Xiao, Jing
    Levit, Noah A.
    Rodriguez Marco, Ainara
    Shabbir, Arsalan
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 34 - 34
  • [33] Long-term safety data for dupilumab up to 4 years in an open-label extension study of adults with moderate-to-severe atopic dermatitis
    Gooderham, Melinda
    Wollenberg, Andreas
    Soong, Weily
    Bissonnette, Robert
    Xiao, Jing
    Khokhar, Faisal A.
    Marco, Ainara Rodriguez
    Levit, Noah A.
    Shabbir, Arsalan
    ALLERGY AND ASTHMA PROCEEDINGS, 2022, 43 (06) : 561 - 561
  • [34] Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)
    Blauvelt, Andrew
    Guttman-Yassky, Emma
    Paller, Amy S.
    Simpson, Eric L.
    Cork, Michael J.
    Weisman, Jamie
    Browning, John
    Soong, Weily
    Sun, Xian
    Chen, Zhen
    Kosloski, Matthew P.
    Kamal, Mohamed A.
    Delevry, Dimittri
    Chuang, Chien-Chia
    O'Malley, John T.
    Bansal, Ashish
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2022, 23 (03) : 365 - 383
  • [35] Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)
    Andrew Blauvelt
    Emma Guttman-Yassky
    Amy S. Paller
    Eric L. Simpson
    Michael J. Cork
    Jamie Weisman
    John Browning
    Weily Soong
    Xian Sun
    Zhen Chen
    Matthew P. Kosloski
    Mohamed A. Kamal
    Dimittri Delevry
    Chien-Chia Chuang
    John T. O’Malley
    Ashish Bansal
    American Journal of Clinical Dermatology, 2022, 23 : 365 - 383
  • [36] An open-label phase IIa trial assessing the pharmacokinetics, safety and efficacy of dupilumab in a paediatric population with moderate-to-severe atopic dermatitis
    Cork, M. J.
    Thaci, D.
    Davis, J. D.
    Zhang, Q.
    Akinlade, B.
    Graham, N. M. H.
    Pirozzi, G.
    Bansal, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 : 67 - 68
  • [37] Efficacy and safety of switching from dupilumab to upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension trial
    Blauvelt, A.
    Ladizinski, B.
    Prajapati, V. H.
    Laquer, V.
    Fischer, A.
    Eisman, S.
    Wu, T.
    Vigna, N.
    Teixeira, H. D.
    Liu, J.
    Eyerich, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E142 - E142
  • [38] An open-label phase IIa trial assessing the pharmacokinetics, safety and efficacy of dupilumab in a paediatric population with moderate-to-severe atopic dermatitis
    Cork, M. J.
    Thaci, D.
    Davis, J. D.
    Zhang, Q.
    Akinlade, B.
    Graham, N. M. H.
    Pirozzi, G.
    Bansal, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 : 155 - 155
  • [39] SAFETY AND EFFICACY OF OPEN-LABEL DUPILUMAB IN ADULT PATIENTS WITH ATOPIC DERMATITIS: AN INTERIM ANALYSIS AT WEEK 76
    Gebauer, Kurt
    Rubel, Diana
    Deleuran, Mette
    Thaci, Diamant
    Boguniewicz, Mark
    Bissonnette, Robert
    Chen, Zhen
    Gadkari, Abhijit
    Eckert, Laurent
    Rossi, Ana B.
    Ardeleanu, Marius
    INTERNAL MEDICINE JOURNAL, 2019, 49 : 19 - 19
  • [40] EFFICACY OF DUPILUMAB IN A 5-YEAR OPEN-LABEL EXTENSION STUDY OF ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Beck, L.
    Deleuran, M.
    Gonzalez, T.
    Xiao, J.
    Avetisova, E.
    Dubost-Brama, A.
    Shabbir, A.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S90 - S91
12345